Invesco Biotechnology & Genome ETF PBE
103.90 USD +1.56 (+1.52%)
Nov 4, 2026, 2:46 PM EST
103.10 Day range 104.52
75.10 52-week range 104.52
- YTD
- +26.48%
- 1 year
- +40.86%
- Market cap
- 312.01M
- EPS (ttm)
- 3.66
- P/E ratio
- 28.37
- YTD return
- +26.48%
- 1-year return
- +40.86%
- Volume
- 17.55K
- Avg volume
- 19.36K
- Open
- 104.55
- Previous close
- 102.34
- Day's range
- 103.10 – 104.52
- 52-week range
- 75.10 – 104.52
6M +23.20 (+28.75%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 69.17
- 200-day average
- 67.04
About Invesco Biotechnology & Genome ETF
The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index. The underlying index was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.
News
Why Healthcare ETFs Are Hovering Around One-Year Highs 
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? 
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? 
Which Healthcare ETF Is the Better Buy: Fidelity’s Broad FHLC or Invesco’s Biotech-Focused PBE? 
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets 
PBE vs. RSPH: Is a Biotech ETF or Equal-Weight Healthcare ETF the Better Choice for Investors? 
iShares' IYH or Invesco's PBE: Which Healthcare ETF Is the Better Long-Term Buy? 
Pharma ETF or Biotech ETF: Which Matches Your Investing Mindset? 
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? 
VanEck Pharmaceutical ETF vs. Invesco Biotech ETF: Which Fund Fits Your Investing Style?
Your note
Sign in to keep a note on PBE — it syncs with the Stock Master app.